Dihua Yu

Early placenta insulin-like growth factor (pro-EPIL) is overexpressed and secreted by c-erbB-2-positive cells with high invasion potential.

Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.

Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis.

ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma.

Characterization of 11 human sarcoma cell strains: evaluation of cytogenetics, tumorigenicity, metastasis, and production of angiogenic factors.

Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.

ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.

Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.

Silibinin: a thorny therapeutic for EGF-R expressing tumors?

Liposomal mediated transfer of ErbB2 antisense DNA: coming of age in the war against cancer.

Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line.

PI3K: Missense Mutation Motivates Malignancy.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.

Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.

Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation.

Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.

A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.

ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.

A knotty turnabout?: Akt1 as a metastasis suppressor.

Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells.

Mechanisms of trastuzumab resistance and their clinical implications.

ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.

Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells.

Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.

Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.

Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers.

Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis.

Adenoviral-Vector Based siRNA for Mutant K-ras as a Promising Tool for Lung Cancer Gene Therapy: A License to Kill.

Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC.

High prevalence of p53 exon 4 mutations in soft tissue sarcoma.

Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation.

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

Molecular mechanisms of erbB2-mediated breast cancer chemoresistance.

Novel approaches for chemosensitization of breast cancer cells: the E1A story.

Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.

ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation.

14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling.

Ph.D. Training in cancer biology.

Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.

Oxygen sensor boosts growth factor signaling.

14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival.

14-3-3zeta/tau heterodimers regulate Slingshot activity in migrating keratinocytes.

ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.

Breast cancer metastasis: challenges and opportunities.

14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition.

Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation.

Molecular predictors of response to trastuzumab and lapatinib in breast cancer.

Invasive breast cancer development: "fatal accident" from malfunctions in both "motor" and "brake".

PI(3)king apart PTEN's role in cancer.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis.

Cancer cell stiffness: integrated roles of three-dimensional matrix stiffness and transforming potential.

Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells.

Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis.

14-3-3ζ as a prognostic marker and therapeutic target for cancer.

Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.

Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data.

p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs.

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.

Cancer cell migration: integrated roles of matrix mechanics and transforming potential.

Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways.

Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells.

Microenvironment determinants of brain metastasis.

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment.

Nucleolin protein interacts with microprocessor complex to affect biogenesis of microRNAs 15a and 16.

Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.

Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.

The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis.

Growth factor signaling in metastasis: current understanding and future opportunities.

Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.

SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases.

Needle-based fluorescence endomicroscopy via structured illumination with a plastic, achromatic objective.

Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis.

14-3-3ζ orchestrates mammary tumor onset and progression via miR-221-mediated cell proliferation.

Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.

Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.

Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer.

Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis.

MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer.

S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer.

HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.

Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.

14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2.

PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.

Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases.

Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.

Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth.

Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer.

Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells.

Upregulation of lactate dehydrogenase a by 14-3-3ζ leads to increased glycolysis critical for breast cancer initiation and progression.

Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib.

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.

Deubiquitination and Stabilization of PD-L1 by CSN5.

Advances in decoding breast cancer brain metastasis.

Brain metastasis: Unique challenges and open opportunities.